Maxime RangerPhD, MBA
Since January 2023, Maxime has been appointed as Executive Chairman of Giiant Pharma, after more than 2 years as CEO. As a serial entrepreneur, Maxime played a leading role in the creation and management of Mperia therapeutics, Inversago Pharma, SemaThera and Neurasic Therapeutics, to name a few.
Chief Executive Officer
After synthetic organic chemistry training at Université de Montréal and a post-doc at MIT, Christophe benefited from the large number of opportunities offered to innovative medicinal chemists at Merck Frosst. His entrepreneurial spirit let him to contribute significantly to the initial tools necessary to start two medicinal chemistry programs.
Board of Directors
AQC/CQDM joint seat
Genesys Capital is one of the largest Canadian- based venture capital firms exclusively focused on the life sciences industry. Genesys is focused on building companies in the high-growth sectors of healthcare and biotechnology. Through its expertise and network, Genesys Capital accelerates the development of commercially viable emerging companies that represent promising life sciences investment opportunities.
The Fonds de solidarité FTQ is investing in a better society thanks to its over 700,000 shareholder-savers. Through its private equity and venture capital investments, the Fonds seeks to have a positive impact on society, namely in the health, environmental and innovation sectors. With net assets of $15.6 billion as at November 30, 2020, the Fonds supported over 3,300 partner companies and more than 220,000 jobs.
AmorChem is a leading early-stage venture fund dedicated to creating the next generation of biotech companies from academic research. Since 2011, with $87 million under management, AmorChem has financed over 33 research programs in academia and accelerated the spin-off and creation of several biotech companies, each with its own ground-breaking therapeutic paradigm. Overall it has led to ten startup companies where AmorChem played a role as founding investor.
Founded in 2010, Crystal Pharmatech is a technology-driven contract research organization, providing comprehensive solutions in solid-state research, crystallization development, pre-formulation studies and formulation development to large pharma corporations and biotech companies. Based in Suzhou (China), New Jersey (USA) and Toronto (Canada), the company has supported the solid-state research and pre-formulation studies of more than 1500 compounds for over 800 clients from USA and China.
AQC Capital is an early-stage Venture Capital fund with over 150 M$ in assets under management to support Quebec’s start-up ecosystem. Investing alongside successful angels, members of the Anges Québec Network, the AQC Capital team offers active and dynamic support in addition to the capital needed by entrepreneurs to reach new heights. As of today, AQC Capital has invested in 53 innovative companies.
CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that will accelerate the discovery and development of safer and more effective drugs. We bring together world-class pharmaceutical corporations, several Canadian biotech companies, the best scientists from both the public and private sectors, as well as the Canadian and Quebec governments. CQDM’s collaborative approach bridges the funding gap needed to drive innovation across the academic and private sectors, especially where early-stage research is concerned.
Anges Québec is a leader in the Québec early-stage investment ecosystem. To date, its 230 Angel Investors have invested more than $117 million in the Québec economy, counting more than 157 companies in its portfolio.